Kyowa Hakko extends US dipeptide focus

By Neil Merrett

- Last updated on GMT

Related tags: Amino acid

Ingredients maker Kyowa Hakko has announced a new partnership with
US-based Austin Chemical Company to market and sell its Sustamine
product in North America.

The company claims that Sustamine, a L-Alanyl-L-Glutamine ingredient derived from the L-Alanine and L-Glutamine amino acids, can offer a number of formulation applications for nutraceutical health and sport nutrition, as well as wider healthcare use. ​Current estimates regarding the worldwide market for Sustamine are over 250 metric tonnes (MT), according to Kyowa Hakko. The company says that by working with the Austin Chemical Company, it can broaden its marketing reach for the product in Canada and the US, particularly in cell culture media. Stability ​A spokesperson for the group said that as an L-Alanyl-L-Glutamine, Sustamine offers a more stable higher yield product when grown in liquid or gel-based cell culture media compared to regular L-Glutamine, which breaks down easily. The group suggests that the product can offer a number of benefits for beverage and healthcare manufacturers. "The product can be used as a stable form of the amino acid L-Glutamine in ready-to-drink formulations and will assist with hydration and electrolyte replacement- critical for sports specific formulations,"​ the spokesperson said. Sustamine ​ The Sustamine dipeptide is formed through a fermentation technology that can directly connect two amino acids without requiring a chemical modification during the process, the manufacturer says. This ensures that the product can be formed directly from glucose as opposed to having to manufacture from two separate amino acids, the spokesperson added."Sustamine can be used in a powder or sold applications, but is best suited for use in liquids."

Related topics: Suppliers

Related news

Follow us

Featured Events

View more

Products

View more

Webinars